<DOC>
	<DOCNO>NCT00006119</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness hydroxyurea treat patient recurrent and/or unresectable meningioma .</brief_summary>
	<brief_title>Hydroxyurea Treating Patients With Recurrent and/or Unresectable Meningioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete , partial , stable response hydroxyurea patient recurrent and/or nonresectable meningioma . - Determine response 2 year regimen patient . - Determine overall disease free survival patient regimen . - Determine quality life patient . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients stratify accord grade disease ( I vs II III ) . Patients receive oral hydroxyurea daily 2 year . Quality life assess treatment , every 3 month 2 year . PROJECTED ACCRUAL : A total 60 patient ( 30 per stratum ) accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven progressive meningioma curable surgery PATIENT CHARACTERISTICS : Age : 16 Performance status : Karnofsky 70100 % Life expectancy : Over 3 month Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST ALT great 2 time ULN Alkaline phosphatase great 2 time ULN Renal : Creatinine great 2 time ULN Other : Not pregnant nursing Fertile patient must use effective contraception 6 month study No malignancy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Concurrent corticosteroid allow control intracranial pressure Radiotherapy : Prior radiotherapy allow No concurrent radiotherapy Surgery : See Disease Characteristics Other : At least 1 year since prior experimental therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult grade I meningioma</keyword>
	<keyword>adult grade II meningioma</keyword>
</DOC>